Analysts’ Weekly Ratings Updates for Amicus Therapeutics (FOLD)

Amicus Therapeutics (NASDAQ: FOLD) recently received a number of ratings updates from brokerages and research firms:

• 11/16/2024 – Amicus Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/12/2024 – Amicus Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an “overweight” rating on the stock.
• 11/8/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/7/2024 – Amicus Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $20.00 to $21.00. They now have an “overweight” rating on the stock.
• 11/7/2024 – Amicus Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/7/2024 – Amicus Therapeutics had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/23/2024 – Amicus Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/17/2024 – Amicus Therapeutics had its price target raised by analysts at Bank of America Co. from $13.00 to $15.00. They now have a “buy” rating on the stock.
• 10/15/2024 – Amicus Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/11/2024 – Amicus Therapeutics had its price target lowered by analysts at Morgan Stanley from $19.00 to $18.00. They now have an “overweight” rating on the stock.
• 10/7/2024 – Amicus Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $9.96 on Thursday. The company’s 50-day simple moving average is $10.77 and its two-hundred day simple moving average is $10.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a market capitalization of $2.98 billion, a P/E ratio of -29.29 and a beta of 0.68.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,398,532.40. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 30,401 shares of company stock worth $352,038 in the last ninety days. 2.20% of the stock is owned by company insiders.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. purchased a new stake in shares of Amicus Therapeutics during the 2nd quarter worth $8,386,000. M&G Plc raised its stake in shares of Amicus Therapeutics by 12.4% during the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Amicus Therapeutics by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after acquiring an additional 7,304 shares during the last quarter. Fiera Capital Corp boosted its stake in Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares in the last quarter. Finally, Mutual of America Capital Management LLC grew its holdings in Amicus Therapeutics by 24.2% in the second quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock worth $2,483,000 after purchasing an additional 48,802 shares during the last quarter.

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.